Monte Rosa Therapeutics announced positive interim data from the Phase 1 study of MRT-8102, showing significant reductions in C-reactive protein levels in subjects with elevated cardiovascular disease risk.
MRT-8102 is a NEK7-directed molecular glue degrader developed for NLRP3/IL-1/IL-6 driven inflammatory diseases.
The study demonstrated rapid and durable reductions in systemic inflammation and favorable safety profiles.
CRP Reductions
After 4 weeks of treatment, C-reactive protein levels were reduced by 85%, with 94% of participants achieving values below 2 mg/L.
NEK7 Degradation
SAD and MAD cohorts showed deep and sustained NEK7 degradation at doses ranging from 5 mg to 400 mg.
GFORCE-1 Study Expansion
The ongoing GFORCE-1 Study in subjects with elevated CVD risk has expanded to accelerate development in atherosclerotic cardiovascular disease.
Upcoming Phase 2 Study
Monte Rosa plans to initiate a Phase 2 ASCVD study in 2026, exploring additional indications for MRT-8102.
Conference Call
A conference call and webcast were planned for Jan. 7, 2026, to discuss the positive interim data of MRT-8102.
- MRT-8102 showcased remarkable results with significant reductions in CRP levels, suggesting potential in treating cardiovascular and cardiometabolic diseases.
- The study demonstrated broad safe dosing ranges and substantial degradation of NEK7, IL-1β, and IL-6 across all dose levels.
- Expansion of proof-of-concept GFORCE-1 study and evaluation of additional Phase 2 studies indicate a promising future for MRT-8102 in treating multiple chronic inflammatory diseases.
The interim data from the Phase 1 study of MRT-8102 highlight its potential as a transformative treatment for cardiovascular and inflammatory diseases. With robust results and ongoing studies, Monte Rosa Therapeutics is poised for significant advancements in the medical field.